DAFTAR PUSTAKA

Ahmad, Y., & Lip, G. Y., 2012, Anticoagulation in Atrial Fibrillation, *Arrhythmia & Electrophysiology Review*, *1*(1), 12–16.

Anderson, B. J., 2008, Paracetamol (Acetaminophen): mechanisms of action, *Paediatric Anaesthesia*, *18*(10), 915–921.

Australian Drug Evaluation Committee, 2021, April 15, *Prescribing medicines in pregnancy database* (AU) [Text], Therapeutic Goods Administration (TGA); Australian Government Department of Health. https://www.tga.gov.au/prescribing-medicines-pregnancy-database

Awaliyah, V. I., 2019, Pola Peresepan Obat Anti-Inflamasi Nonsteroid Pada Pasien Rawat Jalan di Puskesmas Pondok Cabe Ilir Kota Tangerang Selatan pada Bulan Januari-Maret 2019, *Https://Repository.Uinjkt.Ac.Id/*.

Badan Penelitian dan Pengembangan Kesehatan, 2019, *Laporan Nasional Riskesdas 2018*, Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan.

Behnen, E. M. T., 2014, *Ask the Expert: Which NSAIDs Are Most Selective For COX-1 and COX-2?*, Practical Pain Management. https://www.practicalpainmanagement.com/treatments/pharmacological/non-opioids/ask-expert-which-nsaids-are-most-selective-cox-1-cox-2

Boyce, M. L., Zayac, A., Davis, A., Badrick, T., Anoopkumar-Dukie, S., & Bernaitis, N., 2018, Impact of Aspirin on Warfarin Control as Measured by Time in Therapeutic Range, *Basic & Clinical Pharmacology & Toxicology*, *123*(4), 504–508.

BPOM, 2022, *INFORMASI UNTUK DOKTER STATUS PRODUK OBAT AINS COX-2 SELEKTIF INHIBITOR & NON-SELEKTIF INHIBITOR*. https://www.pom.go.id/new/view/more/berita/114/INFORMASI-UNTUK-DOKTER-STATUS-PRODUK-OBAT-AINS-COX-2-SELEKTIF-INHIBITOR---NON-SELEKTIF-INHIBITOR.html

Cannegieter, S. C., Rosendaal, F. R., & Briët, E., 1994, Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses, *Circulation*, *89*(2), 635–641.

Caughey, G., Cleland, L., Penglis, P., Gamble, J., & James, M., 2001, Roles of Cyclooxygenase (COX)-1 and COX-2 in Prostanoid Production by Human Endothelial Cells: Selective Up-Regulation of Prostacyclin Synthesis by COX-2, *Journal of Immunology (Baltimore, Md. : 1950)*, *167*, 2831–2838.

Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., & Fuchs, C. S., 2006, Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events, *Circulation*, *113*(12), 1578–1587.

Chan, T. Y., 1995, Adverse Interactions Between Warfarin and Nonsteroidal Antiinflammatory Drugs: Mechanisms, Clinical Significance, and Avoidance, *Annals of Pharmacotherapy*, *29*(12), 1274–1283.

Choi, K. H., Kim, A. J., Son, I. J., Kim, K.-H., Kim, K.-B., Ahn, H., & Lee, E. B., 2010, Risk Factors of Drug Interaction between Warfarin and Nonsteroidal Anti-Inflammatory Drugs in Practical Setting, *Journal of Korean Medical Science*, *25*(3), 337–341.

Dagenais, S., & Haldeman, S., 2012, CHAPTER 2 - Guide to Using This Textbook, In S. Dagenais & S. Haldeman (Eds.), *Evidence-Based Management of Low Back Pain* (pp. 13–20), Mosby.

Dasgupta, A., & Wahed, A., 2014, Chapter 20 - Pharmacogenomics, In A. Dasgupta & A. Wahed (Eds.), *Clinical Chemistry, Immunology and Laboratory Quality Control* (pp. 353–362), Elsevier.

Dechanont, S., Maphanta, S., Butthum, B., & Kongkaew, C., 2014, Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis, *Pharmacoepidemiology and Drug Safety*, *23*(5), 489–497.

Dentali, F., Douketis, J. D., Woods, K., Thabane, L., Foster, G., Holbrook, A., & Crowther, M., 2006, Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial, *The Annals of Pharmacotherapy*, *40*(7–8), 1241–1247.

Fedan, J. S., 2007, Thrombosis-Embolism, In *xPharm: The Comprehensive Pharmacology Reference* (pp. 1–11), Elsevier.

Ferner, R. E., Dear, J. W., & Bateman, D. N., 2011, Management of paracetamol poisoning, *BMJ (Clinical Research Ed.)*, *342*, d2218.

Forrest, J. A. H., Clements, J. A., & Prescott, L. F., 1982, Clinical Pharmacokinetics of Paracetamol, *Clinical Pharmacokinetics*, *7*(2), 93–107.

Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J., 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, *JAMA*, *285*(22), 2864–2870.

Gagne, J. J., Maio, V., & Rabinowitz, C., 2008, Prevalence and predictors of potential drug–drug interactions in Regione Emilia-Romagna, Italy, *Journal of Clinical Pharmacy and Therapeutics*, *33*(2), 141–151.

Gallus, A. S., Baker, R. I., Chong, B. H., Ockelford, P. A., & Street, A. M., 2000, Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis, *The Medical Journal of Australia*, *172*(12), 600–605.

Ghlichloo, I., & Gerriets, V., 2021, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), In *StatPearls*, StatPearls Publishing.

Gunaydin, C., & Bilge, S. S., 2018, Effects of Nonsteroidal Anti-Inflammatory Drugs at the Molecular Level, *The Eurasian Journal of Medicine*, *50*(2), 116–121.

Günther, A., & Ruppert, C., 2006, Anticoagulants, In *Encyclopedia of Respiratory Medicine* (pp. 115–128), Academic Press.

Haines, S., Zeolla, M., & Witt, D., 2005, Venous thromboembolism, In *DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach* (6th ed., pp. 389–395), McGraw-Hill.

Harder, S., & Thürmann, P., 1996, Clinically Important Drug Interactions with Anticoagulants, *Clinical Pharmacokinetics*, *30*(6), 416–444.

Harirforoosh, S., Asghar, W., & Jamali, F., 2013, Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications, *Journal of Pharmacy & Pharmaceutical Sciences: A Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques*, *16*(5), 821–847.

Hc, D., R, W., Gy, L., & Sh, H., 2012, Stroke prevention in atrial fibrillation: do we still need warfarin?, *Current Opinion in Neurology*, *25*(1).

Herman, D., Locatelli, I., Grabnar, I., Peternel, P., Stegnar, M., Mrhar, A., Breskvar, K., & Dolzan, V., 2005, Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose, *The Pharmacogenomics Journal*, *5*(3), 193–202.

Hirsh, J., Fuster, V., Ansell, J., & Halperin, J. L., 2003, American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy, *Circulation*, *107*(12), 1692–1711.

Holford, N. H. G., 1986, Clinical Pharmacokinetics and Pharmacodynamics of Warfarin: Understanding the Dose-Effect Relationship, *Clinical Pharmacokinetics*, *11*(6), 483–504.

Jacobs, L. G., 2008, Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly, *Cardiology Clinics*, *26*(2), 157–167, v.

Jaffer, I. H., & Weitz, J. I., 2018, Chapter 149 - Antithrombotic Drugs, In R. Hoffman, E. J. Benz, L. E. Silberstein, H. E. Heslop, J. I. Weitz, J. Anastasi, M. E. Salama, & S. A. Abutalib (Eds.), *Hematology (Seventh Edition)* (pp. 2168–2188), Elsevier.

Karim, A., Tolbert, D., Piergies, A., Hubbard, R. C., Harper, K., Wallemark, C. B., Slater, M., & Geis, G. S., 2000, Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects, *Journal of Clinical Pharmacology*, *40*(6), 655–663.

Kotirum, S., Chaiyakunapruk, N., Jampachaisri, K., Wattanasombat, S., & Rojnuckarin, P., 2007, Utilization review of concomitant use of potentially interacting drugs in Thai patients using warfarin therapy, *Pharmacoepidemiology and Drug Safety*, *16*(2), 216–222.

Kumar, B., & Swee, M. L., 2015, Nonsteroidal Anti-inflammatory Drug Use in a Patient With Hypertension: A Teachable Moment, *JAMA Internal Medicine*, *175*(6), 892–893.

Kwan, D., Bartle, W. R., & Walker, S. E., 1999, The Effects of Acetaminophen on Pharmacokinetics and Pharmacodynamics of Warfarin, *The Journal of Clinical Pharmacology*, *39*(1), 68–75.

Launiainen, T., Sajantila, A., Rasanen, I., Vuori, E., & Ojanperä, I., 2010, Adverse interaction of warfarin and paracetamol: evidence from a post-mortem study, *European Journal of Clinical Pharmacology*, *66*(1), 97–103.

Leong, D., & Wu, P. E., 2020, Warfarin and acetaminophen interaction in a 47-year-old woman, *CMAJ : Canadian Medical Association Journal = Journal de l'Association Medicale Canadienne*, *192*(19), E506–E508.

Mahé, I., Bertrand, N., Drouet, L., Sollier, C. B. D., Simoneau, G., Mazoyer, E., Caulin, C., & Bergmann, J.-F., 2006, Interaction between paracetamol and warfarin in patients: A double-blind, placebo-controlled, randomized study, *Haematologica*, *91*(12), 1621–1627, Scopus.

Majerus, P., Broze, G., Miletich, J., & Tollefsen, D., 1996, Anticoagulant thrombolytic, and antiplatelet drugs, In *Hardman JG, Limbird LE, eds. Goodman and Gilman's The pharmacological basis of therapeutics* (9th ed., pp. 51–1347), McGraw-Hill.

McCrae, J. C., Morrison, E. E., MacIntyre, I. M., Dear, J. W., & Webb, D. J., 2018, Long-term adverse effects of paracetamol – a review, *British Journal of Clinical Pharmacology*, *84*(10), 2218–2230.

Meegaard, P. M., Holck, L. H. V., Pottegard, A., Madsen, H., & Hallas, J., 2012, Excessive anticoagulation with warfarin or phenprocoumon may have multiple causes, *Danish Medical Journal*, *59*(2), 1–5.

Micromedex, 2022, *Micromedex Drug-Reax® (Truven Health Analytics, Greenwood Village, Colorado, USA)*. https://www.micromedexsolutions.com/

Nesheiwat, Z., Goyal, A., & Jagtap, M., 2021, Atrial Fibrillation, In *StatPearls [Internet]*, StatPearls Publishing.

Odutayo, A., Wong, C. X., Hsiao, A. J., Hopewell, S., Altman, D. G., & Emdin, C. A., 2016, Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis, *BMJ*, *354*, i4482.

Oertel, B., & Lötsch, J., 2007, NSAIDs, Pharmacokinetics, In R. F. Schmidt & W. D. Willis (Eds.), *Encyclopedia of Pain* (pp. 1479–1487), Springer Berlin Heidelberg.

Park, K., & Bavry, A. A., 2014, Risk of stroke associated with nonsteroidal anti-inflammatory drugs, *Vascular Health and Risk Management*, *10*, 25–32.

Penner, J., & Abbrecht, P., 1975, Lack of interaction between ibuprofen and warfarin, *Current Therapeutic Research*, *18*, 862–871.

Prasetyaningrum, E., & Wahyu, A., 2018, POLA PENGGUNAAN OBAT ANALGETIK NON OPIOID PADA MASYARAKAT DESA LIMBANGAN KABUPATEN KENDAL, *Jurnal Farmasi & Sains Indonesia*, *1*(1), 72–76.

Quest, D. W., 2008, Stockley's drug interactions. 8th edition; Stockley's drug interactions 2008 pocket companion, *Canadian Family Physician*, *54*(7), 1025.

Roblek, T., Vaupotic, T., Mrhar, A., & Lainscak, M., 2015, Drug-drug interaction software in clinical practice: a systematic review, *European Journal of Clinical Pharmacology*, *71*(2), 131–142.

Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H.-J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., Müller, C. R., Strom, T. M., & Oldenburg, J., 2004, Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2, *Nature*, *427*(6974), 537–541.

Royston, D., 2013, Anticoagulant and Antiplatelet Therapy, In *Pharmacology and Physiology for Anesthesia* (pp. 643–667), Elsevier.

Sabzwari, S. R., Qidwai, W., & Bhanji, S., 2013, Polypharmacy in elderly: a cautious trail to tread, *JPMA. The Journal of the Pakistan Medical Association*, *63*(5), 624–627.

Sayhan, M. B., Oguz, S., Yüksel, V., Hüseyin, S., Sayhan, E. S., & Yagci, G., 2014, The Analysis of Patients Admitted to the Emergency Department Due to Complications Related to Warfarin Treatment, *Journal of Academic Emergency Medicine*, *13*(4), 194–198.

Schulman, S., & Aisenberg, J., 2018, Are NSAIDs Double Trouble?∗, *Journal of the American College of Cardiology*, *72*(3), 268–270.

Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N., 2008, Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment, *Chest*, *133*(6), 257S-298S.

Schwartz, J. I., Agrawal, N. G. B., Hartford, A. H., Cote, J., Hunt, T. L., Verbesselt, R., Eckols, D. R., & Gottesdiener, K. M., 2007, The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin, *Journal of Clinical Pharmacology*, *47*(5), 620–627.

Scully, C., 2013, Agents used in the treatment of patients with orofacial disease, In *Oral and Maxillofacial Medicine* (pp. 48–79), Elsevier.

Shen, A. Y.-J., Yao, J. F., Brar, S. S., Jorgensen, M. B., & Chen, W., 2007, Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation, *Journal of the American College of Cardiology*, *50*(4), 309–315.

Smith, M., 2011, *Contraindications to the initiation of oral anticoagulants and anti-platelet agents in patients with atrial fibrillation in primary care*, National Health Service.

Sönnerstam, E., Sjölander, M., Lövheim, H., & Gustafsson, M., 2018, Clinically relevant drug-drug interactions among elderly people with dementia, *European Journal of Clinical Pharmacology*, *74*(10), 1351–1360.

Tadros, R., & Shakib, S., 2010, Warfarin--indications, risks and drug interactions, *Australian Family Physician*, *39*(7), 476–479.

Takigawa, T., Tainaka, H., Mihara, K., & Ogata, H., 1998, Inhibition of S-Warfarin Metabolism by Nonsteroidal Antiinflammatory Drugs in Human Liver

Microsomes in Vitro., *Biological and Pharmaceutical Bulletin*, *21*(5), 541–543.

Teklay, G., Shiferaw, N., Legesse, B., & Bekele, M. L., 2014, Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: A prospective observational study, *Thrombosis Journal*, *12*(1), Scopus.

Thijssen, H. H., Soute, B. A., Vervoort, L. M., & Claessens, J. G., 2004, Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle, *Thrombosis and Haemostasis*, *92*(4), 797–802.

Türck, D., Su, C. A., Heinzel, G., Busch, U., Bluhmki, E., & Hoffmann, J., 1997, Lack of interaction between meloxicam and warfarin in healthy volunteers, *European Journal of Clinical Pharmacology*, *51*(5), 421–425.

Ucar, M., Alagozlu, H., Sahin, S., & Ozdemir, O., 2013, The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin, *Medicinski Glasnik : Official Publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina*, *10*(1), 50–54.

Uygungül, E., Ayrik, C., Narci, H., Erdoğan, S., Toker, İ., Demir, F., & Karaaslan, U., 2014, Determining Risk Factors of Bleeding in Patients on Warfarin Treatment, *Advances in Hematology*, *2014*.

Vane, J. R., 1971, Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs, *Nature New Biology*, *231*(25), 232–235.

Vitry, A. I., Roughead, E. E., Ramsay, E. N., Preiss, A. K., Ryan, P., Gilbert, A. L., Caughey, G. E., Shakib, S., Esterman, A., Zhang, Y., & McDermott, R. A., 2011, Major bleeding risk associated with warfarin and co-medications in the elderly population, *Pharmacoepidemiology and Drug Safety*, *20*(10), 1057–1063.

Vonbach, P., Dubied, A., Krähenbühl, S., & Beer, J. H., 2008, Evaluation of frequently used drug interaction screening programs, *Pharmacy World & Science: PWS*, *30*(4), 367–374.

WHO, 2020a, *Global Health Estimates: Life expectancy and leading causes of death and disability*. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates#

WHO, 2020b, *Top 10 causes of death in Indonesia for both sexes aged all ages (2019)*. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death

Wiwanitkit, V., 2006, Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations, *Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis*, *12*(2), 219–222.

Wongrakpanich, S., Wongrakpanich, A., Melhado, K., & Rangaswami, J., 2018, A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly, *Aging and Disease*, *9*(1), 143–150.

Yasar, Ü., Eliasson, E., Dahl, M.-L., Johansson, I., Ingelman-Sundberg, M., & Sjöqvist, F., 1999, Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish Population, *Biochemical and Biophysical Research Communications*, *254*(3), 628–631.

Zhang, Q., Bal-dit-Sollier, C., Drouet, L., Simoneau, G., Alvarez, J.-C., Pruvot, S., Aubourg, R., Berge, N., Bergmann, J.-F., Mouly, S., & Mahé, I., 2011, Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial, *European Journal of Clinical Pharmacology*, *67*(3), 309–314.

Zhou, M., Leonard, C. E., Brensinger, C. M., Bilker, W. B., Kimmel, S. E., Hecht, T. E. H., & Hennessy, S., 2020, Pharmacoepidemiologic Screening of Potential Oral Anticoagulant Drug Interactions Leading to Thromboembolic Events, *Clinical Pharmacology and Therapeutics*, *108*(2), 377–386, Scopus.